Details of today's analyst meeting from Bloomberg:
Warner-Lambert Plans to Spend $1.17 Billion on R&D in 1999
news.com
New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of
Lipitor, the top-selling cholesterol-reducing drug in the U.S.,
said it will spend $1.17 billion on research and development this
year, up 51 percent from $777 million last year.
Warner-Lambert Expects 30% EPS Increase in 1999, 20% in 2000
news.com
New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of
Lipitor, the top-selling cholesterol-reducing drug in the U.S.,
said it expects to increase earnings per share by 30 percent in
1999 from $1.48 last year.
The company is expected to earn $1.93 a share in 1999, the
average estimate of analysts polled by First Call Corp. Warner-
Lambert said at an analysts' meeting in New York that it expects
earnings of about $1.92 for the year.
The Morris Plains, New Jersey-based company said it expects
20 percent earnings growth in 2000. Sales of Lipitor, which the
company said will grow 50 percent to $3.3 billion this year, are
helping to fuel the increase in profit.
Warner-Lambert Expects 1999 Celexa Sales of $300 Mln in U.S.
news.com
New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of
Lipitor, the top-selling cholesterol-reducing drug in the U.S.,
said sales of the antidepressant Celexa could reach $300 million
this year in the U.S.
The comments were made at an analysts' meeting in New York.
Celexa, a drug marketed by Warner-Lambert and Forest Laboratories
Inc., was introduced in the U.S. in 1998. The drug has been
taking market share away from Eli Lilly & Co.'s Prozac.
Celexa could eventually capture 15 to 20 percent of the U.S.
market, Warner-Lambert said.
Warner-Lambert Plans to Compare Rezulin With Avandia, Actos
news.com
New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of
Lipitor, the top-selling cholesterol-reducing drug in the U.S.,
said it plans to do studies comparing its diabetes pill, Rezulin,
with two rival drugs expected to win U.S. approval this year.
Rezulin, which Warner-Lambert licenses from Japan's Sankyo
Co., has been linked to about 38 cases of death and serious liver
damage. The drug has been prescribed for more than 1.5 million
people since its 1997 introduction.
Warner-Lambert Expects Lipitor Sales of $3.3 Bln This Year
news.com
New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of
Lipitor, the top-selling cholesterol-reducing drug in the U.S.,
said it expects sales of the drug to increase 50 percent to $3.3
billion in 1999 worldwide and $4 billion in 2000. |
